CH625253A5 - - Google Patents

Download PDF

Info

Publication number
CH625253A5
CH625253A5 CH1231476A CH1231476A CH625253A5 CH 625253 A5 CH625253 A5 CH 625253A5 CH 1231476 A CH1231476 A CH 1231476A CH 1231476 A CH1231476 A CH 1231476A CH 625253 A5 CH625253 A5 CH 625253A5
Authority
CH
Switzerland
Prior art keywords
hydroxy
oestran
compounds
formula
steroid
Prior art date
Application number
CH1231476A
Other languages
German (de)
English (en)
Inventor
Henry A Strade
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/618,176 external-priority patent/US4004005A/en
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of CH625253A5 publication Critical patent/CH625253A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CH1231476A 1975-09-30 1976-09-29 CH625253A5 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/618,176 US4004005A (en) 1975-09-30 1975-09-30 Steroidal erythropoietic agents and therapeutic compositions and methods
US05/693,249 US4049805A (en) 1975-09-30 1976-06-04 Steroidal erythropoietic agents and therapeutic compositions and methods

Publications (1)

Publication Number Publication Date
CH625253A5 true CH625253A5 (fr) 1981-09-15

Family

ID=27088168

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1231476A CH625253A5 (fr) 1975-09-30 1976-09-29

Country Status (10)

Country Link
US (1) US4049805A (fr)
JP (1) JPS5262263A (fr)
CH (1) CH625253A5 (fr)
DE (1) DE2643936A1 (fr)
DK (1) DK145859C (fr)
FR (1) FR2326198A1 (fr)
GB (1) GB1565229A (fr)
IE (1) IE43859B1 (fr)
LU (1) LU75901A1 (fr)
NL (1) NL7610812A (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330611A1 (fr) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Molecules bifonctionnelles et therapies basees sur celles-ci
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
NZ525830A (en) * 2000-10-13 2005-07-29 Norwood Immunology Ltd Disease prevention by reactivation of the thymus
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
SI1889198T1 (sl) 2005-04-28 2015-02-27 Proteus Digital Health, Inc. Farma-informacijski sistem
WO2007035716A2 (fr) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions de proteines rap specifiques des proteines contenant du cr, et leurs utilisations
WO2010095940A2 (fr) 2009-02-20 2010-08-26 To-Bbb Holding B.V. Sustème d'administration de médicament à base de glutathionne
NZ596876A (en) 2009-05-06 2014-01-31 Lab Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same

Also Published As

Publication number Publication date
NL7610812A (nl) 1977-04-01
FR2326198A1 (fr) 1977-04-29
LU75901A1 (fr) 1977-05-11
US4049805A (en) 1977-09-20
DK437976A (da) 1977-03-31
GB1565229A (en) 1980-04-16
DK145859C (da) 1983-10-03
IE43859L (en) 1977-03-30
DE2643936A1 (de) 1977-03-31
JPS5262263A (en) 1977-05-23
DK145859B (da) 1983-03-21
IE43859B1 (en) 1981-06-17
FR2326198B1 (fr) 1980-10-10

Similar Documents

Publication Publication Date Title
CH625253A5 (fr)
CH641352A5 (de) 15-(hydroxy-, acyloxy- oder oxo-)steroide enthaltende mittel zur hemmung der biosynthese der mevalonsaeure.
DE1801750A1 (de) Von Prostaglandinen abgeleitete Verbindungen und Verfahren zu ihrer Herstellung
DE2265138B2 (de) Vincaminsäure-benzylester, dessen Salze mit Säuren, ein Verfahren zu ihrer Herstellung und pharmazeutische Mittel
CH621560A5 (en) Process for the preparation of 3-ketosteroids disubstituted in position 16
US4004005A (en) Steroidal erythropoietic agents and therapeutic compositions and methods
DE2624177A1 (de) Verfahren zur herstellung von m-benzoylhydratropsaeure
DE2515142B2 (de) Oral verabfolgbare mittel zur senkung des lipid- und cholesterin- spiegels
DE957030C (de) Verfahren zur Herstellung der Phenylpropionsaeureester von Steroidhormonen
DE1468919C (de) 3,11 Dioxo steroid 4,9 diene und ein Verfahren zu ihrer Herstellung
DE1668857C (de) 6 alpha, 9 alpha Difluorprednisolon 17 valerat 21 acetat
AT390255B (de) Verfahren zur herstellung von cis-3-hydroxyprolin durch trans-cis-isomerisierung von trans-3hydroxyprolin
DE1939164A1 (de) 14beta-Hydroxy-15alpha-acyloxy-cardenolide
AT208526B (de) Verfahren zur Herstellung von neuen Estern des Testosterons und 19-Nortestosterons
EP0007347A1 (fr) Dérivés de alkylène glycol abaissant le taux en lipide et procédés pour leur préparation.
DE2307795C3 (de) 11 beta 17alpha, 21 Trihydroxy-6
DE2145686C3 (de) 2-Chlor-S-sulfamylbenzoesäurederivate, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
DE965637C (de) Verfahren zur Herstellung von 19-Nortestosteron-17-acylaten und bzw. oder deren 3-Enolacylaten
CH687001A5 (de) Pharmazeutisches Praeparat zur Modulierung der Immunreaktion.
EP0437694A1 (fr) Utilisation de l'acide hydroxyoctadécadiène carboxylique, sa forme kéto-oxydée et leurs dérivés pour le traitement des maladies estrogénodépendantes, et compositions pharmaceutiques les contenant
DE912695C (de) Verfahren zur Herstellung eines Oestradiolesters
DE2344749A1 (de) Arzneimittel auf basis von androst3-en-17-ol und seinen estern
DE1668857B1 (de) 6alpha,9alpha-Difluorprednisolon-17-valerat-21-acetat
DE1102145B (de) Verfahren zur Herstellung von therapeutisch wirksamen Monoacylaten des Pregnan- bzw.Allopregnan-3ª‰, 16ª‡-diol-20-ons
DE1107225B (de) Verfahren zur Herstellung von 1, 4, 17(20)-Pregnatrienen

Legal Events

Date Code Title Description
PL Patent ceased